Nicox Appoints Doug Hubatsch as New Chief Scientific Officer to Lead Clinical and Non-Clinical Development
December 13, 2021 at 01:30 am
Nicox SA announced the appointment of Doug Hubatsch to lead all of the Companys non-clinical and clinical development activities. As Chief Scientific Officer, Doug Hubatsch will be responsible for setting the research and development strategy of the Group and will be a member of the Nicox Executive Committee, reporting to Michele Garufi, Chief Executive Officer. He will be based in Nicoxs US subsidiary Nicox Ophthalmics Inc., in Durham, North Carolina. Doug Hubatsch joins Nicox from Novartis Pharmaceuticals, where he was Global Medical Head for Ocular Surface Disease and Digital Medicines within Global Medical Affairs.